fluoxetine has been researched along with Parkinson Disease in 36 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)." | 7.81 | Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015) |
| "There are no effective treatments for multiple system atrophy (MSA)." | 7.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| "The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported." | 6.42 | [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003) |
| "To examine the effects of fluoxetine and repetitive transcranial magnetic stimulation (rTMS) on regional cerebral blood flow (rCBF) using SPECT in patients with PD and depression." | 5.12 | Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. ( Barbosa, ER; Bermpohl, F; Buchpiguel, C; Fregni, F; Marcolin, MA; Ono, CR; Pascual-Leone, A; Santos, CM; Valente, KD, 2006) |
| "We report here the case of a patient with fluoxetine and selegiline induced serotonin syndrome, which presented as encephalopathy, generalized myoclonias, fever, stiffness and sweating, complicated with acute renal failure, rhabdomyolysis and disseminated intravascular coagulation findings." | 4.81 | [Serotonin syndrome: report of a fatal case and review of the literature]. ( Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N, 2002) |
| "The cardinal motor symptoms of Parkinson's disease (PD) include resting tremor, akinesia, bradykinesia, and rigidity, and these motor abnormalities can be modeled in rodents by administration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one; TBZ)." | 3.81 | Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. ( Contreras-Mora, HM; Correa, M; Milligan, MN; Podurgiel, SJ; Purcell, LJ; Salamone, JD; Yohn, SE, 2015) |
| "The accumulation of alpha-synuclein in Lewy bodies and Lewy neurites of different neuronal populations is one of the neuropathological hallmarks in Parkinson disease (PD)." | 3.78 | Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. ( Barlow, C; Carter, T; Kohl, Z; Mante, M; Masliah, E; Münch, M; Rockenstein, E; Ubhi, K; Winkler, J; Winner, B, 2012) |
| "A selective, sensitive, simple, and rapid method for the simultaneous determination of fluoxetine (FL) and norfluoxetine (nor-FL) was developed and validated, and further applied to analyze plasma samples obtained from FL-treated patients with Parkinson disease (n = 18)." | 3.73 | Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study. ( Djordjevic, S; Kovacevic, I; Miljkovic, B; Pokrajac, M; Vuksanovic, J, 2005) |
| "There are no effective treatments for multiple system atrophy (MSA)." | 3.01 | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. ( Azulay, JP; Cochen de Cock, V; Corvol, JC; Couratier, P; Damier, P; Defebvre, L; Durif, F; Fabbri, M; Foubert-Samier, A; Geny, C; Houeto, JL; Meissner, WG; Pavy-Le Traon, A; Perez-Lloret, S; Rascol, O; Remy, P; Rousseau, V; Sommet, A; Thalamas, C; Tison, F; Tranchant, C; Verin, M, 2021) |
| "The unified Parkinson's disease rating scale (UPDRS), activities of daily living (ADL), Hamilton rating scale for depression (HRSD), Beck depression inventory (BDI), and mini-mental state examination (MMSE) were assessed by a rater blinded to treatment arm." | 2.71 | Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. ( Barbosa, ER; Fregni, F; Gallucci-Neto, J; Marcolin, MA; Myczkowski, ML; Pascual-Leone, A; Rigolino, R; Santos, CM; Valente, KD, 2004) |
| "All records were reviewed from a Parkinson's disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine." | 2.67 | Fluoxetine and selegiline--lack of significant interaction. ( Waters, CH, 1994) |
| "The occurrence of a pathological gambling behavior in a 61-year-old patient with idiopathic Parkinson's disease treated with dopaminergic drugs is reported." | 2.42 | [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. ( Bagheri, H; Montastruc, JL; Schmitt, L, 2003) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| " The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole." | 1.40 | Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease. ( Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J, 2014) |
| " However, long-term administration of L-DOPA can induce abnormal side effects." | 1.38 | Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. ( Abe, M; Inden, M; Kitamura, Y; Minamino, H; Takata, K; Tooyama, I; Yoshimoto, K, 2012) |
| "Treatment with fluoxetine (10 mg/kg, i." | 1.31 | Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. ( Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H, 2001) |
| "Depression is commonly associated with idiopathic Parkinson's disease." | 1.29 | Anticholinergic effects in a depressed parkinsonian patient. ( Huszonek, JJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (36.11) | 18.2507 |
| 2000's | 13 (36.11) | 29.6817 |
| 2010's | 9 (25.00) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Rascol, O | 4 |
| Cochen de Cock, V | 1 |
| Pavy-Le Traon, A | 1 |
| Foubert-Samier, A | 1 |
| Thalamas, C | 1 |
| Sommet, A | 1 |
| Rousseau, V | 1 |
| Perez-Lloret, S | 1 |
| Fabbri, M | 1 |
| Azulay, JP | 1 |
| Corvol, JC | 1 |
| Couratier, P | 1 |
| Damier, P | 1 |
| Defebvre, L | 1 |
| Durif, F | 1 |
| Geny, C | 1 |
| Houeto, JL | 1 |
| Remy, P | 1 |
| Tranchant, C | 1 |
| Verin, M | 1 |
| Tison, F | 1 |
| Meissner, WG | 1 |
| Kim, KI | 1 |
| Chung, YC | 1 |
| Jin, BK | 1 |
| Kostić, V | 1 |
| Dzoljić, E | 1 |
| Todorović, Z | 1 |
| Mijajlović, M | 1 |
| Svetel, M | 1 |
| Stefanova, E | 1 |
| Dragasević, N | 1 |
| Petrović, I | 1 |
| Milosević, M | 1 |
| Kovacević, I | 2 |
| Miljković, B | 2 |
| Pokrajac, M | 2 |
| Prostran, M | 1 |
| Sharifi, H | 1 |
| Nayebi, AM | 1 |
| Farajnia, S | 1 |
| Haddadi, R | 1 |
| Berghauzen-Maciejewska, K | 1 |
| Kuter, K | 1 |
| Kolasiewicz, W | 1 |
| Głowacka, U | 1 |
| Dziubina, A | 1 |
| Ossowska, K | 1 |
| Wardas, J | 1 |
| Podurgiel, SJ | 1 |
| Milligan, MN | 1 |
| Yohn, SE | 1 |
| Purcell, LJ | 1 |
| Contreras-Mora, HM | 1 |
| Correa, M | 1 |
| Salamone, JD | 1 |
| Demchuk, ND | 1 |
| Shutov, AA | 1 |
| McMillan, PJ | 1 |
| White, SS | 1 |
| Franklin, A | 1 |
| Greenup, JL | 1 |
| Leverenz, JB | 1 |
| Raskind, MA | 1 |
| Szot, P | 1 |
| Zhang, F | 1 |
| Zhou, H | 1 |
| Wilson, BC | 1 |
| Shi, JS | 1 |
| Hong, JS | 1 |
| Gao, HM | 1 |
| Kohl, Z | 1 |
| Winner, B | 1 |
| Ubhi, K | 1 |
| Rockenstein, E | 1 |
| Mante, M | 1 |
| Münch, M | 1 |
| Barlow, C | 1 |
| Carter, T | 1 |
| Masliah, E | 1 |
| Winkler, J | 1 |
| Inden, M | 1 |
| Abe, M | 1 |
| Minamino, H | 1 |
| Takata, K | 1 |
| Yoshimoto, K | 1 |
| Tooyama, I | 1 |
| Kitamura, Y | 1 |
| Montastruc, JL | 4 |
| Schmitt, L | 1 |
| Bagheri, H | 1 |
| Fregni, F | 4 |
| Santos, CM | 2 |
| Myczkowski, ML | 1 |
| Rigolino, R | 1 |
| Gallucci-Neto, J | 1 |
| Barbosa, ER | 3 |
| Valente, KD | 2 |
| Pascual-Leone, A | 3 |
| Marcolin, MA | 3 |
| Djordjevic, S | 1 |
| Vuksanovic, J | 1 |
| Boggio, PS | 2 |
| Bermpohl, F | 2 |
| Mansur, CG | 1 |
| Rosa, M | 1 |
| Rumi, DO | 1 |
| Odebrecht Rosa, M | 1 |
| Rigonatti, SP | 2 |
| Araujo Silva, MT | 1 |
| Lee, KH | 1 |
| Blaha, CD | 1 |
| Harris, BT | 1 |
| Cooper, S | 1 |
| Hitti, FL | 1 |
| Leiter, JC | 1 |
| Roberts, DW | 1 |
| Kim, U | 1 |
| Ono, CR | 1 |
| Buchpiguel, C | 1 |
| Cardoso, EF | 1 |
| Martins Maia, F | 1 |
| Luis Myczkowski, M | 1 |
| Coracini, K | 1 |
| Lopes Vieira, A | 1 |
| Melo, LM | 1 |
| Sato, JR | 1 |
| Antonio Marcolin, M | 1 |
| Cruz, AC | 1 |
| Reis Barbosa, E | 1 |
| Amaro, E | 1 |
| Preskorn, SH | 2 |
| Garcia-Monco, JC | 1 |
| Padierna, A | 1 |
| Gomez Beldarrain, M | 1 |
| Fabre, N | 1 |
| Blin, O | 2 |
| Senard, JM | 3 |
| Rascol, A | 2 |
| Huszonek, JJ | 1 |
| Waters, CH | 1 |
| Chamontin, B | 1 |
| Tran, MA | 2 |
| Llau, ME | 1 |
| Toyama, SC | 1 |
| Iacono, RP | 1 |
| Lauterbach, EC | 1 |
| Hesselink, JM | 1 |
| Pelat, M | 1 |
| Verwaerde, P | 1 |
| Brefel-Courbon, C | 1 |
| Shad, MU | 1 |
| Marsh, C | 1 |
| Yamato, H | 1 |
| Kannari, K | 1 |
| Shen, H | 1 |
| Suda, T | 1 |
| Matsunaga, M | 1 |
| Bilbao Garay, J | 1 |
| Mesa Plaza, N | 1 |
| Castilla Castellano, V | 1 |
| Dhimes Tejada, P | 1 |
| Jermain, DM | 1 |
| Hughes, PL | 1 |
| Follender, AB | 1 |
| Caley, CF | 1 |
| Friedman, JH | 1 |
| Jansen, EN | 1 |
| Kölling, P | 1 |
| Suchowersky, O | 1 |
| deVries, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Depression in Amyotrophic Lateral Sclerosis[NCT03892863] | 0 participants (Actual) | Interventional | 2019-11-15 | Withdrawn (stopped due to Participants were not able to stay for two weeks near our center.) | |||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
3 reviews available for fluoxetine and Parkinson Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Topics: Antidepressive Agents; Antiparkinson Agents; Bromocriptine; Citalopram; Depressive Disorder; Dopamin | 2003 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism | 2002 |
10 trials available for fluoxetine and Parkinson Disease
| Article | Year |
|---|---|
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
Topics: Double-Blind Method; Fluoxetine; Humans; Multiple System Atrophy; Parkinson Disease; Quality of Life | 2021 |
Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.
Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Dementia; Depression; | 2012 |
[Correction of motor and affective symptoms of parkinsonism by selective serotonine reuptake inhibition antidepressant].
Topics: Adult; Aged; Female; Fluoxetine; Humans; Male; Middle Aged; Mood Disorders; Parkinson Disease; Psych | 2008 |
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric | 2004 |
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric | 2004 |
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric | 2004 |
Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electric | 2004 |
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression.
Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Fe | 2005 |
Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD.
Topics: Aged; Antidepressive Agents; Brain; Cerebrovascular Circulation; Combined Modality Therapy; Depressi | 2006 |
rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex.
Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Brain Mapping; Combined Modality Therapy; De | 2008 |
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
Topics: Aged; Drug Therapy, Combination; Female; Fluoxetine; Humans; Levodopa; Male; Neurologic Examination; | 1995 |
Fluoxetine and selegiline--lack of significant interaction.
Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; | 1994 |
Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.
Topics: Aged; Aged, 80 and over; Animals; Blood Pressure; Denervation; Disease Models, Animal; Dogs; Female; | 1998 |
23 other studies available for fluoxetine and Parkinson Disease
| Article | Year |
|---|---|
Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopaminergic Neurons; | 2018 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonist | 2014 |
Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Rela | 2015 |
Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding Sites; Cell Count; Dopamine beta-Hydroxylase; Fe | 2011 |
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity.
Topics: Animals; Cells, Cultured; Female; Fluoxetine; Microglia; Neurons; Neuroprotective Agents; Neurotoxic | 2012 |
Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.
Topics: Adult; alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Cell Proliferation; Disease Mode | 2012 |
Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Fluoxetine; Histones; Levodopa; Ma | 2012 |
Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study.
Topics: Adult; Aged; Chromatography, Liquid; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Mas | 2005 |
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease.
Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; | 2006 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; | 2008 |
Selegiline, fluoxetine, and depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Ther | 1995 |
Anticholinergic effects in a depressed parkinsonian patient.
Topics: Aged; Benztropine; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1995 |
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline.
Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Diagnosis, Differential; Drug Interactions; Female; | 1993 |
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease | 1994 |
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Diseas | 1993 |
Serotonin and Parkinson's disease.
Topics: Basal Ganglia Diseases; Depressive Disorder; Dopamine; Drug Therapy, Combination; Fluoxetine; Humans | 1993 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Halo | 2001 |
Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Extr | 2001 |
Potential fluoxetine-selegiline interaction.
Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegili | 1992 |
Does fluoxetine exacerbate Parkinson's disease?
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Humans; Male; | 1992 |
[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
Topics: Depression; Female; Fluoxetine; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, | 1992 |
Possible interactions between deprenyl and prozac.
Topics: Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Parkinson Disease; Selegiline | 1990 |